Uncategorized

NewLimit snags $435M after seeing age reversal in human liver cells

NewLimit snags $435M after seeing age reversal in human liver cells

Published

on

NewLimit is pressing the gas, speeding into clinical trials much sooner than expected after lab research showed its epigenetic reprogramming asset reversed aging in human liver cells.​ ​Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version